New eye drops aim to improve corneal transplant outcomes in fuchs dystrophy
NCT ID NCT07024693
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental eye drop called DT-168 in people with Fuchs endothelial corneal dystrophy who are already scheduled for a corneal transplant. The goal is to see if the drops are safe and affect disease-related markers. About 28 adults aged 30 and older with a specific genetic change will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUCHS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
DTX-168-201 Study Site
RECRUITINGIndianapolis, Indiana, 46260, United States
-
DTX-168-201 Study Site
RECRUITINGGrand Rapids, Michigan, 49546, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye drops offer a new way to treat fuchs dystrophy?
- Fuchs dystrophy and cataract surgery: does the cornea behave differently?
- One shot to see clearly: cell therapy takes on corneal edema
- Which corneal transplant is best? 1,000-Patient study aims to find out
- Corneal polishing study aims to improve cell therapy for fuchs dystrophy
- New eye drops aim to speed vision recovery after cornea surgery